CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $22.45M, lower than 95% of all stocks globally
- PositionCurrent ratio is 0.76×, lower than 95% of its Biotechnology peers (median 5.64×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
260.90MCHF325.75M · vs all stocks (USD)
Revenue (TTM)
17.98MEUR22.45M · vs all stocks (USD)
Profit Margin
-69.22%vs Biotechnology peers
Beta
0.7340xvs all stocks
52-Week Change
45.98%vs all stocks
Market Capitalization
260.90MCHF325.75M · vs all stocks (USD)
Enterprise Value
252.54MCHF315.31M · vs all stocks (USD)
Forward P/E
17.28xvs Biotechnology peers
Price to Sales (TTM)
14.12xvs Biotechnology peers
Enterprise to Revenue
14.05xvs Biotechnology peers
Enterprise to EBITDA
-57.46xvs Biotechnology peers
Profit Margin
-69.22%vs Biotechnology peers
Operating Margin
-83.59%vs Biotechnology peers
Return on Assets (TTM)
-5.65%vs Biotechnology peers
Revenue (TTM)
17.98MEUR22.45M · vs all stocks (USD)
Revenue per Share (TTM)
0.9580EURUpdated Aug 22, 2026Quarterly Revenue Growth
-84.90%vs Biotechnology peers
Gross Profit (TTM)
17.98MEUR22.45M · vs all stocks (USD)
EBITDA (TTM)
-4.40MEUR-5.49M · vs all stocks (USD)
Net Income (TTM)
-12.44MEUR-15.54M · vs all stocks (USD)
Operating Cash Flow (TTM)
30.41MEUR37.96M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
36.96MEUR46.15M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00CHFUpdated Aug 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
19.13MEURFY2025 · Dec 31, 2025Operating Income
-4.70MEUR-5.49M · vs all stocks (USD)
Pre-tax Income
-12.35MEURFY2025 · Dec 31, 2025Income Tax Expense
885.00KEURFY2025 · Dec 31, 2025Net Income
-13.24MEURFY2025 · Dec 31, 2025EBIT
-7.96MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
-7.78MEURFY2025 · Dec 31, 2025Research & Development
15.12MEURFY2025 · Dec 31, 2025Selling, General & Administrative
4.85MEURFY2025 · Dec 31, 2025Non-operating Interest Income
539.00KEURFY2025 · Dec 31, 2025Non-operating Interest Expense
4.40MEURFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00EURFY2025 · Dec 31, 2025Operating Cash Flow
31.93MEURFY2025 · Dec 31, 2025Free Cash Flow
31.88MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
12.19MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-12.35MEURFY2025 · Dec 31, 2025Stock-based Compensation
212.00KEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
44.07MEURFY2025 · Dec 31, 2025Capital Expenditures
-47.00KEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.00KEURFY2025 · Dec 31, 2025Purchase of Investments
-18.41MEURFY2025 · Dec 31, 2025Sale of Investments
4.79MEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-13.66MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-13.58MEURFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-13.58MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
-26.82MEURFY2025 · Dec 31, 2025Shares Outstanding
20.01MSharesUpdated Aug 22, 2026Float Shares
17.99MSharesUpdated Aug 22, 2026% Held by Insiders
13.11%vs all stocks
% Held by Institutions
10.68%vs all stocks
Total Cash (MRQ)
27.14MEUR33.89M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.44EURUpdated Aug 22, 2026Total Debt (MRQ)
35.87MEUR44.79M · vs all stocks (USD)
Current Ratio (MRQ)
0.7600xvs Biotechnology peers
Book Value per Share (MRQ)
-0.5228EURUpdated Aug 22, 2026Total Assets
40.05MEUR46.79M · vs all stocks (USD)
Total Current Assets
38.08MEURFY2025 · Dec 31, 2025Total Liabilities
51.19MEURFY2025 · Dec 31, 2025Total Non-current Assets
1.98MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
1.06MEURFY2025 · Dec 31, 2025Total Current Liabilities
50.13MEURFY2025 · Dec 31, 2025Cash
12.19MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
12.19MEURFY2025 · Dec 31, 2025Other Short-term Investments
16.69MEURFY2025 · Dec 31, 2025Accounts Receivable
2.54MEURFY2025 · Dec 31, 2025Accounts Payable
2.32MEURFY2025 · Dec 31, 2025Short-term Debt
37.58MEURFY2025 · Dec 31, 2025Long-term Debt
583.00KEURFY2025 · Dec 31, 2025Common Stock (Book)
4.00MEURFY2025 · Dec 31, 2025Retained Earnings
-18.27MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
-11.13MEUR-13.01M · vs all stocks (USD)
52-Week Low
7.80CHFUpdated Aug 22, 202652-Week High
31.85CHFUpdated Aug 22, 202652-Week Change
45.98%vs all stocks
Beta
0.7340xvs all stocks
50-Day MA
12.07CHFUpdated Aug 22, 2026200-Day MA
16.48CHFUpdated Aug 22, 2026Avg 10-Day Volume
46.18KSharesUpdated Aug 22, 2026Avg 30-Day Volume
47.80KSharesUpdated Aug 22, 2026Diluted EPS (TTM)
-0.6200EURUpdated Aug 22, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.76×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.76Industry median: 5.64Industry P5: 1.06Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $22.45M, lower than 95% of all stocks globallySignificant
Revenue (USD): 22,446,024.873Global P5: 30,274,777.221
Levered free cash flow is $46.15M, above the global median of $16.24MNotable
Levered free cash flow (USD): 46,150,869.069Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Lyell Immunopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hubei Guangji Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cuorips Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vanda Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Golden Throat Holdings Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inhibikase Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tellgen Corporation
Tier 1ProductionApproval-Gated PipelineRule
Dishman Carbogen Amcis Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Shanxi C&Y Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hunan Yujing Machinery Co., Ltd.
1 interpretationCash-Flow Ratios Elevated
Mastercard Incorporated
1 interpretationCash-Flow Ratios Elevated
Johnson Fine Chemical Co., Ltd.
1 interpretationCash-Flow Ratios Elevated